MabVax Therapeutics Holdings, Inc.
http://www.mabvax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MabVax Therapeutics Holdings, Inc.
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
France's Pharnext Undone By Placebo Effect
The Paris-based biotech's Charcot-Marie-Tooth disease drug falls short in Phase III.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- MabVax Therapeutics, Inc.
- Telik, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice